Study #2023-0880
A phase II trial utilizing Metronidazole to optimize the microbiome of rectal adenocarcinoma undergoing neoadjuvant therapy
MD Anderson Study Status
Enrolling
Treatment Agent
Metronidazole
Description
To learn if adding metronidazole to standard therapy can decrease populations of Fusobacterium nucleatum (F. nucleatum) and other anaerobes (small organisms that cause infections) in participants with rectal cancer receiving neoadjuvant therapy, compared to neoadjuvant therapy alone.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Rectal Adenocarcinoma
Study phase:
Phase II
Physician name:
Michael White
Department:
Colon and Rectal Surgery
For general questions about clinical trials:
1-844-539-2756
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.